Far Infrared Radiation Treatment for Prostate Cancer

Prostatic Neoplasms Clinical Trial

Official title:

Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Prostate Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00573820
• Other study ID #: GAAD-PC-CTP1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: December 12, 2007
• Last updated: August 14, 2009
• Start date: January 2006
• Est. completion date: December 2008

Study information

• Verified date: August 2009
• Source: GAAD Medical Research Institute Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

A study to determine the use of far infrared radiation for the treatment of prostate cancer.

Description:

Our initial assessment indicates that electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to cure a number of diseases, including prostate cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4
• Est. completion date: December 2008
• Est. primary completion date: February 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Persons with Prostate, Bladder or Testicular Cancer.

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostatic Neoplasms

Intervention

Radiation:
• Far Infrared Radiation
Far Infrared Radiation (5µm to 20µm wavelength) for 30 to 40 minutes each treatment session.

Locations

Country	Name	City	State
Canada	The Centre for Incurable Diseases	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary end point is to determine the therapeutic effects of far infrared radiation on Prostate Cancer.		2 years and 6 months	No
Secondary	The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of cancer (Bladder and Testis).		2 years and 6 months	No